T. Rowe Price Associates, Inc. 13D and 13G filings for Akero Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-11-14 12:19 pm Purchase | 2025-09-30 | 13G | Akero Therapeutics, Inc. AKRO | T. Rowe Price Associates, Inc. | 3,810,076 4.800% | 1,717 (+0.05%) | Filing |
| 2024-11-14 1:22 pm Purchase | 2024-09-30 | 13G | Akero Therapeutics, Inc. AKRO | T. Rowe Price Associates, Inc. | 3,808,359 5.500% | 127,150 (+3.45%) | Filing |
| 2024-02-14 10:03 am Purchase | 2023-12-31 | 13G | Akero Therapeutics, Inc. AKRO | T. Rowe Price Associates, Inc. | 3,681,209 6.600% | 1,280,172 (+53.32%) | Filing |
| 2023-02-14 12:38 pm Purchase | 2022-12-31 | 13G | Akero Therapeutics, Inc. AKRO | T. Rowe Price Associates, Inc. | 2,401,037 5.100% | 2,401,037 (New Position) | Filing |